vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and Westrock Coffee Co (WEST). Click either name above to swap in a different company.
Westrock Coffee Co is the larger business by last-quarter revenue ($339.5M vs $284.0M, roughly 1.2× ACADIA PHARMACEUTICALS INC). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs -6.6%, a 103.0% gap on every dollar of revenue. On growth, Westrock Coffee Co posted the faster year-over-year revenue change (48.3% vs 9.4%). Over the past eight quarters, Westrock Coffee Co's revenue compounded faster (32.8% CAGR vs 17.5%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Westrock Coffee Co is a global integrated coffee, tea and functional beverage solutions provider. It sources, roasts, manufactures and distributes coffee products, ready-to-drink beverages and custom formulations for retail, foodservice and commercial clients across North America and other key markets.
ACAD vs WEST — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $339.5M |
| Net Profit | $273.6M | $-22.6M |
| Gross Margin | 90.8% | 11.5% |
| Operating Margin | 6.1% | -2.6% |
| Net Margin | 96.3% | -6.6% |
| Revenue YoY | 9.4% | 48.3% |
| Net Profit YoY | 90.3% | 8.3% |
| EPS (diluted) | $1.61 | $-0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $339.5M | ||
| Q3 25 | $278.6M | $354.8M | ||
| Q2 25 | $264.6M | $280.9M | ||
| Q1 25 | $244.3M | $213.8M | ||
| Q4 24 | $259.6M | $229.0M | ||
| Q3 24 | $250.4M | $220.9M | ||
| Q2 24 | $242.0M | $208.4M | ||
| Q1 24 | $205.8M | $192.5M |
| Q4 25 | $273.6M | $-22.6M | ||
| Q3 25 | $71.8M | $-19.1M | ||
| Q2 25 | $26.7M | $-21.6M | ||
| Q1 25 | $19.0M | $-27.2M | ||
| Q4 24 | $143.7M | $-24.6M | ||
| Q3 24 | $32.8M | $-14.3M | ||
| Q2 24 | $33.4M | $-17.8M | ||
| Q1 24 | $16.6M | $-23.7M |
| Q4 25 | 90.8% | 11.5% | ||
| Q3 25 | 92.2% | 11.7% | ||
| Q2 25 | 92.2% | 14.7% | ||
| Q1 25 | 91.7% | 13.6% | ||
| Q4 24 | 91.6% | 16.6% | ||
| Q3 24 | 92.5% | 16.8% | ||
| Q2 24 | 92.5% | 19.9% | ||
| Q1 24 | 88.8% | 19.4% |
| Q4 25 | 6.1% | -2.6% | ||
| Q3 25 | 12.8% | -2.4% | ||
| Q2 25 | 12.2% | -5.3% | ||
| Q1 25 | 7.9% | -6.1% | ||
| Q4 24 | 59.1% | -4.3% | ||
| Q3 24 | 12.6% | -5.8% | ||
| Q2 24 | 12.6% | -7.9% | ||
| Q1 24 | 7.4% | -5.3% |
| Q4 25 | 96.3% | -6.6% | ||
| Q3 25 | 25.8% | -5.4% | ||
| Q2 25 | 10.1% | -7.7% | ||
| Q1 25 | 7.8% | -12.7% | ||
| Q4 24 | 55.4% | -10.7% | ||
| Q3 24 | 13.1% | -6.5% | ||
| Q2 24 | 13.8% | -8.5% | ||
| Q1 24 | 8.0% | -12.3% |
| Q4 25 | $1.61 | $-0.22 | ||
| Q3 25 | $0.42 | $-0.20 | ||
| Q2 25 | $0.16 | $-0.23 | ||
| Q1 25 | $0.11 | $-0.29 | ||
| Q4 24 | $0.86 | $-0.26 | ||
| Q3 24 | $0.20 | $-0.16 | ||
| Q2 24 | $0.20 | $-0.20 | ||
| Q1 24 | $0.10 | $-0.27 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $49.9M |
| Total DebtLower is stronger | — | $444.1M |
| Stockholders' EquityBook value | $1.2B | $-1.9M |
| Total Assets | $1.6B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $49.9M | ||
| Q3 25 | $258.0M | $34.0M | ||
| Q2 25 | $253.6M | $44.0M | ||
| Q1 25 | $217.7M | $33.1M | ||
| Q4 24 | $319.6M | $26.2M | ||
| Q3 24 | $155.1M | $22.4M | ||
| Q2 24 | $177.1M | $24.3M | ||
| Q1 24 | $204.7M | $12.6M |
| Q4 25 | — | $444.1M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $393.1M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $1.2B | $-1.9M | ||
| Q3 25 | $917.3M | $11.4M | ||
| Q2 25 | $822.4M | $18.2M | ||
| Q1 25 | $765.2M | $71.4M | ||
| Q4 24 | $732.8M | $97.5M | ||
| Q3 24 | $577.2M | $110.3M | ||
| Q2 24 | $516.7M | $81.5M | ||
| Q1 24 | $464.0M | $91.7M |
| Q4 25 | $1.6B | $1.2B | ||
| Q3 25 | $1.3B | $1.2B | ||
| Q2 25 | $1.2B | $1.2B | ||
| Q1 25 | $1.1B | $1.1B | ||
| Q4 24 | $1.2B | $1.1B | ||
| Q3 24 | $976.9M | $1.1B | ||
| Q2 24 | $914.1M | $1.1B | ||
| Q1 24 | $855.1M | $983.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 4.03× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $36.7M |
| Free Cash FlowOCF − Capex | — | $27.8M |
| FCF MarginFCF / Revenue | — | 8.2% |
| Capex IntensityCapex / Revenue | — | 2.6% |
| Cash ConversionOCF / Net Profit | -0.18× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-107.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $36.7M | ||
| Q3 25 | $74.3M | $-26.6M | ||
| Q2 25 | $64.0M | $-7.0M | ||
| Q1 25 | $20.3M | $-22.1M | ||
| Q4 24 | $40.4M | $2.8M | ||
| Q3 24 | $63.2M | $-332.0K | ||
| Q2 24 | $25.0M | $-23.7M | ||
| Q1 24 | $29.1M | $8.0M |
| Q4 25 | — | $27.8M | ||
| Q3 25 | $73.9M | $-44.7M | ||
| Q2 25 | — | $-27.5M | ||
| Q1 25 | — | $-63.4M | ||
| Q4 24 | — | $-15.4M | ||
| Q3 24 | $63.2M | $-36.7M | ||
| Q2 24 | — | $-59.9M | ||
| Q1 24 | — | $-60.9M |
| Q4 25 | — | 8.2% | ||
| Q3 25 | 26.5% | -12.6% | ||
| Q2 25 | — | -9.8% | ||
| Q1 25 | — | -29.7% | ||
| Q4 24 | — | -6.7% | ||
| Q3 24 | 25.2% | -16.6% | ||
| Q2 24 | — | -28.7% | ||
| Q1 24 | — | -31.7% |
| Q4 25 | — | 2.6% | ||
| Q3 25 | 0.1% | 5.1% | ||
| Q2 25 | — | 7.3% | ||
| Q1 25 | — | 19.3% | ||
| Q4 24 | — | 7.9% | ||
| Q3 24 | 0.0% | 16.5% | ||
| Q2 24 | — | 17.4% | ||
| Q1 24 | — | 35.8% |
| Q4 25 | -0.18× | — | ||
| Q3 25 | 1.03× | — | ||
| Q2 25 | 2.40× | — | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 1.93× | — | ||
| Q2 24 | 0.75× | — | ||
| Q1 24 | 1.76× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
WEST
| Coffee And Tea | $202.6M | 60% |
| Flavors Extracts And Ingredients | $69.6M | 21% |
| Sustainable Sourcing And Traceability Segments | $66.9M | 20% |
